

For Immediate Release

Nature Study: AI Boosts Access, Equity for Underserved Populations ***Digital Diagnostics Founder Co-Authors Paper on Improving Access to Treatment***

Coralville, Iowa August 27, 2024 – Michael D. Abramoff, MD, PhD, founder and executive chairman of [Digital Diagnostics](#), creator of the [LumineticsCore™](#) AI system for diagnosing diabetic retinopathy, has co-authored a new study on the application of autonomous artificial intelligence and testing for diabetic eye disease (DED). Titled *Autonomous Artificial Intelligence for Diabetic Eye Disease Increases Access and Health Equity in Underserved Populations*, the work was co-authored by experts from Johns Hopkins Medicine and the University of Wisconsin-Madison.

The study, which drew on data from 2019 through 2021, compared adherence to annual DED testing among two groups of Johns Hopkins Medicine patients. One group underwent testing at sites that adopted autonomous AI diagnostic tool, LumineticsCore, while the other group's testing sites continued without AI.

At sites with autonomous AI testing, researchers observed the following changes:

- Clinics equipped with LumineticsCore experienced a 7.6 percentage point greater increase in DED testing than non-AI sites from 2019 to 2021.
- The adherence rate for DED testing among Black/African Americans increased by 12.2 percentage points in clinics using LumineticsCore and decreased by 0.6 percentage points at non-AI sites.
- With LumineticsCore, the adherence rate gap for DED testing between Asian Americans and Black/African Americans shrank from 15.6% in 2019 to 3.5% in 2021.

“One reason that made me create autonomous AI was its potential to address health disparities and improve access equity in care,” said Dr. Abramoff. “These findings are encouraging. They suggest that AI could play a vital role in narrowing health disparities and improving care access for those who historically have been the least likely to receive it. Further research will help to confirm our findings and address other questions about autonomous AI in healthcare.”

To access the full paper follow this link: [Nature](#), and explore an expanded list of relevant publications authored by Abramoff [here](#).

About Digital Diagnostics

Digital Diagnostics Inc. is a pioneering AI diagnostics company on a mission to transform the quality, accessibility, equity, and affordability of global healthcare through the application of technology in the medical diagnosis and treatment process. The company, originally founded by Michael Abramoff, MD, PhD, a neuroscientist, practicing fellowship-trained retina specialist, and computer engineer, is led by him and co-founder and CEO, John Bertrand.

Digital Diagnostics is paving the way for autonomous and assistive AI technology that is free of bias to become a new standard of care, contributing to democratizing healthcare and closing care gaps. The company works closely with patient advocacy groups, provider organizations, regulators, and other quality of care and ethics-focused stakeholders to enable the adoption of healthcare AI. For more information and the latest news follow: <https://digitaldiagnosics.com/>